focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Brazil to seek regulatory approval for AstraZeneca vaccine on Jan. 15

Mon, 28th Dec 2020 21:18

(Adds comments by health official and Bolsonaro, background,
details)

By Pedro Fonseca

RIO DE JANEIRO, Dec 28 (Reuters) - Brazil's Fiocruz
biomedical institute will seek approval for the Oxford
University/AstraZeneca vaccine against COVID-19 with
federal health regulator Anvisa on Jan. 15, one of the center's
senior officials said on Monday.

The Jan. 15 date brings a measure of clarity to Brazil's
vaccine rollout, which critics have blasted for falling behind
smaller and poorer peers in Latin America. The AstraZeneca
vaccine represents the Brazilian government's main bet to help
end the world's second-most deadly coronavirus outbreak, after
the United States.

"The final submission of this process, this last milestone,
will be on Jan. 15," Marco Krieger, vice president of health
production and innovation at the Rio de Janeiro-based Fiocruz
institute, told Reuters.

Once seen as a front-runner in the development of a
coronavirus vaccine, the British team has been overtaken by U.S.
drugmaker Pfizer Inc and partner BioNTech,
whose shots are already being used in Britain and the United
States.

Confusion has arisen over the best dosage. Data published
earlier from the British team's Phase 3 trials showed efficacy
was 62% for trial participants given two full doses, but a more
robust 90% for a sub-group given first a half, then a full dose.

Krieger said Fiocruz would apply to Anvisa with a two-dose
regimen, which, despite being less effective, was more widely
tested, including in Brazil.

He said Fiocruz would be applying for a full approval with
Anvisa, rather than an emergency use application. Pfizer, which
is in talks to sell its vaccine to Brazil's federal government,
has said the emergency use application is onerous.

Krieger said the institute would start filling and finishing
1 million doses per week in January, then ramp up to 3 million
weekly doses in early February.

Fiocruz is licensed to receive supplies from AstraZeneca and
eventually produce the vaccine locally. Brazil's federal
government, which has ordered the AstraZeneca vaccine, expects
to receive 100 million doses in the first half of 2021.

Brazilian President Jair Bolsonaro, one of the world's most
prominent coronavirus skeptics, said over the weekend he was not
worried about criticism over the speed of Brazil's vaccine
rollout, saying he felt no pressure.

"Nobody pressures me for anything, I don't give a damn about
it," he said in a video aired on CNN Brasil.

Bolsonaro, who caught the virus in July, has also said he
will not take any COVID-19 vaccine, adding to growing vaccine
skepticism in Brazil.

Brazil now has nearly 7.5 million confirmed cases, and
191,139 deaths from the virus since the outbreak began,
according to data from the Health Ministry.
(Reporting by Pedro Fonseca in Rio de Janeiro
Writing by Gabriel Stargardter
Editing by Brad Haynes and Matthew Lewis)

More News
Today 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.